Oligonucleotide delivery: a patent review (2010-2013)

Santiago Grijalvo, Anna Aviñó, and Ramon Eritja

Expt. Opin. Ther. Patents, 24(7), 801-819 (2014).

PMID: 24798406, doi: 10.1517/13543776.2014.915944

Abstract

Introduction

The use of aptamers, antisense technology and RNA interference has allowed nucleic acids to be considered promising alternatives to classical drugs. However, nucleic acids face several obstacles and pitfalls in the creation of effective nucleic acid drugs. The development of these approaches has increased the pipeline toward clinical trials.

Areas covered

This review covers research and patent literature of the last three years focused on the development of safe and effective non-viral drug delivery systems for the treatment of diseases such as cancer or genetic disorders by using oligonucleotides.

Expert opinion

The therapeutic applications of oligonucleotides have undergone multiple obstacles especially in biodistribution and cellular internalization. Cationic lipids are the most used vehicles for the preparation of novel formulations. Combinatorial libraries of these compounds and the use of solid lipid nanoparticles carrying these synthetic cationic lipids, cholesterol and polyethyleneglycol have emerged to enhance cellular uptake and biocompatibility of nucleic acids. Besides this extensive use, synthesis of oligonucleotide covalently linked to lipids has also emerged as a promising alternative

to formulations. The use of peptides alone or in combination with lipids is also an expanding field for oligonucleotide delivery. Polymeric platforms are also good candidates as they showed improved cellular uptake, biodegradability, biocompatibility, and the possibility to incorporate several components such as ligands for receptor-mediated endocytosis and molecules to facilitate endosomal escape. Finally, nanomaterials may also play an important role in the future. The last developments showed improved *in vivo* efficacy, thus gaining a foothold in therapeutics.

Keywords

Antisense, aptamers, cell penetration peptides, drug delivery, liposomes, nanoparticles, oligonucleotides, polymers, RNA interference, siRNA

1. Introduction

The search of novel drugs in medicinal chemistry is based on the use of small molecules derived from the screening thousands of compounds along with computational studies that directly interact with target molecules, mainly proteins.

Nucleic acids, in contrast to conventional small drugs, are macromolecules that target specifically messenger RNAs (mRNAs) inhibiting the expression of a known gene sequence. This mode of action, that allows the specific inhibition of a target protein, covers a range of biomedical applications that are not treatable with current drugs [1].

Oligonucleotides face multiple obstacles in order to be considered clinically acceptable therapeutic drugs. They are susceptible to degradation in the presence of nucleases and, because of their size and charge, oligonucleotides do not cross cell membranes by passive diffusion. Chemical biology of nucleic acids has accelerated the process of discovery of modified nucleic acids with an enhanced stability hence protecting them from degradation. Furthermore, these chemical modifications have also allowed the synthesis of novel nucleic acids with more drug-like properties, target affinity and specificity without losing biologic activities of natural nucleic acids [2].

According to Figure 1, we can find at least three potential sites in order to modify chemically oligonucleotides: (a) the sugar ring, (b) the phosphate backbone and (c) the nucleobases. Chemical modifications on the sugar ring affect the stability of the DNA:RNA duplex and therefore improving, in most of the cases, protein binding and resistance to degradation in serum. These 2'-modifications mainly comprise 2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl substituents and bicyclic sugars locked nucleic acids (LNAs), which have the effect to fix the sugar conformations hence increasing the stability of duplexes.

Modifications carried out directly on the phosphate group comprise phosphorothioate (PS) backbones, which is the most common modification in antisense oligonucleotides (ASOs) and siRNAs. Modified ASOs and siRNAs containing PS moieties have shown better stability profiles in serum facilitating intravenous and subcutaneous administrations. In a more radical change, the ribose phosphate backbone has been replaced with morpholino (PMO) moieties, a six-membered ring that has been successfully introduced into antisense oligonucleotides, showing low toxicities and promising activities. Peptide nucleic acids (PNAs) represent other kind of variation comprising the introduction of (2-aminoethyl)-glycine peptide backbones and replacing the corresponding ribose or deoxyribose rings giving strong interactions with RNA molecules. Because PNA are uncharged and have been shown excellent nuclease-resistant molecules, they have been mainly evaluated in many antisense studies [3].

Considerable progresses made by researchers to boost drug-like properties of nucleic acids have allowed the launch of multiple clinical trials [4] for several ASOs and siRNAs (Table 1). To date, there are only a few nucleic acid-based drugs approved by the FDA: Macugen, a RNA aptamer [5] designed for the treatment of age-related macular degeneration; Mipomersen [6], a fully synthetic antisense oligonucleotide against hypercholesterolemia and Vitravene, an antisense oligonucleotide drug to treat cytomegalovirus retinitis in AIDS patients was launched in 1998 [7]. However, despite the increased number of potentially therapeutic nucleic acids, there are only few examples in which non-viral delivery agents have been employed. For instance, the use of either transferrin receptor-targeted nanoparticles (CALAA-01), cationic liposome-based strategies (ALN-TTR, ALN-PCS02, Atu027, TKM-080301) or the use of polymeric nanoparticles (CRLX-101) are in progress. The rest of the modified siRNAs and ASOs that are under active investigation are directly administered in their natural

unmodified form without using any delivery system, being ocular, electroporation, parenteral, intramuscular or systemic the most preferred administration routes.

The ability of oligonucleotides to cross cell membranes is very poor. The use of viral carriers, like retrovirus or adeno-associated virus (AAV) increases the transfection efficiencies of nucleic acids. However, several concerns about the immunogenicity and possible recombination of oncogenes have been expressed [8]. It is for this reason that non-viral carriers have emerged in the last years as safer alternatives inducing less toxicity and immunogenicity although their transfection efficiencies are lower compared to viral vectors [9]. The development of biocompatible materials (Figure 2) such as cationic lipids [10], liposomes [11], stable nucleic acid lipid particles (SNALPs) [12], polymers [13] or cell-penetrating peptides [14] has allowed nucleic acids to bind to non-viral carriers taking advantage of the electrostatic interactions.

The development of covalent strategies has also allowed the synthesis of more stable conjugates containing lipids [15], polymers [16] or dendrimers [17] with oligonucleotides. The use of neutral lipids like cholesterol is one of the preferred strategies for the chemical modification of nucleic acids. In particular, cholesterol-siRNA constructs have considerably improved the cellular uptake properties of siRNA molecules hence facilitating their intravenous administration for silencing ApoB expression with good efficiencies [18]. Nonetheless, despite these promising results, the use of covalent strategies remains scarcely exploited compared to electrostatic formulations, which are being used in the majority of clinical trials in both antisense and RNA interference therapies.

2. Strategies using short nucleic acids as drugs

2.1 Antisense technology and RNA interference

Antisense technology and RNA interference (RNAi) mechanisms are the major processes to control gene expression. In both cases, the expression of disease-causing proteins is down-regulated at the level of mRNA. In the case of antisense technology (Figure 3A), single-stranded ASO molecules are able to interact with target mRNA through Watson-Crick base-pair interactions within hybridization-accessible sites. Depending on the design and the chemistry, the corresponding ASO:RNA hybrid may result in degradation by the action of RNaseH endonuclease that hydrolyzes the duplex, therefore inhibiting the synthesis of proteins. This particular strategy also includes miRNA-based constructs such as antagomirs, locked nucleic acids (LNA) anti-miR, microRNA sponges and miR-masks that have shown good results in gene inhibition.

RNAi mechanism (Figure 3B) is the other approach to control the gene activity. This mechanism occurs in the cytoplasm and is based on the recognition of double-stranded small interference RNA (siRNA) by a multi-protein complex called RNA-induced silencing complex (RISC). First, long double-stranded RNAs (dsRNA) are cleaved by the action of the RNase endonuclease Dicer producing siRNAs. After siRNAs are loaded into the RISC complex, Argonaute-2 protein (Ago-2), which is one of the components of RISC, cleaves and releases the passenger strand of siRNA, leading to an activated form of RISC that contains a guide strand of RNA. The guide strand binds to target mRNA by intermolecular base pairing and mRNA is cleaved thereby inhibiting protein synthesis.

Synthetic miRNA mimics to restore tumor suppressor miRNA-expression Besides cellular uptake limitations, there are two additional hurdles to overcome in RNAi. Synthetic siRNAs in mammalian cells could interfere with the effect produced by

micro-RNAs (miRNAs), which control the efficiency of mRNA translations giving undesirable off-target effects [19]. Moreover, siRNAs can activate the immune response by activating Toll-like receptors leading to unwanted side effects.

2.2 Aptamers

Aptamers are nucleic acids with high affinity to a particular protein. These molecules are initially selected by means of PCR-based techniques, starting from random libraries of short nucleotide segments (SELEX). Interesting applications of aptamers in the biosensing field are related to the analysis of chemical or biological pollutants but ~~also~~ they can also be used as potential drugs [20]. The first aptamer-based drug was approved by the FDA. Pegaptanib or macugen binds the isoform of VEGF₁₆₅ and inhibits its interaction with the VEGF receptor [21] being used in the treatment of age-related macular degeneration.

3. Evaluation of patents

Patent literature in this review is divided into several areas depending on the nature of the compounds used for enhancing cellular uptake.

3.1 Formulations containing cationic lipids

Cationic lipids constitute the main non-viral approach to deliver nucleic acids inside cells. Although there are some limitations associated to their use, such as low transfection efficiencies, toxicity and stability in the presence of serum [22], to date, the design and synthesis of novel cationic lipid libraries and lipid-like molecules has

prompted promising improvements in the delivery of siRNA and ASO molecules in both *in vitro* and *in vivo* experiments [23].

Solid lipid nanoparticles (SLNP) have emerged as an alternative to liposomes. These drug delivery vehicles combine the advantages of lipid emulsions and polymeric nanoparticles and overcome some issues like the stability of the particles *in vivo* [24]. They are composed of cationic lipids to provide higher efficiency in neutralizing the negative charge of nucleic acids by forming tighter complexes; cationic or fusogenic lipids and, finally, hydrophilic molecules such as polyethylene glycol (PEG) derivatives, which generally improve the plasma stability and biodistribution by altering the surface properties of SLNPs.

The therapeutic effects of some SLNPs in RNAi or antisense technology have been reported in multiple *in vivo* experiments and clinical trials for hypercholesterolemia, transthyretin (TTR), solid tumors or cancer treatments (see Table 1) becoming systemic administrations as the most preferred application for these delivery platforms [25, 26].

PEGylated lipids, also known as shielding lipids, are one of the most usual components of SLNPs along with cationic lipids. In general, the role of PEGylated lipids in formulations is mainly based on regulating fusogenicity, shielding surface charges, reducing the particle size and avoiding aggregation during storage [27]. Furthermore, the presence of these shielding lipids in SLNPs normally causes better tolerability *in vivo* hence improving the pharmacokinetic profiles of the particles. In order to increase the efficacy of such SLNPs, some groups have optimized the chemical space by synthesizing combinatorial libraries of novel PEGylated and cationic lipids evaluating their efficiencies in both *in vitro* and *in vivo* studies. In particular, a series of novel PEGylated derivatives have been synthesized and combined with various synthetic

cationic lipids to form the SLNPs formulations. For instance, Alnylam Pharmaceuticals [28, 29] and Abbott Laboratories [30] published several patent applications in which synthetic approaches to obtain a variety of shielding lipids were described. Some of them are displayed in Figure 4A. The strategy followed by Alnylam consisted of fixing the hydrophobic part with a long hydrocarbonated alkyl chain and subsequently varying the hydrophilic part by introducing several series of ethylene glycol derivatives (PEG-C-DMSO, PEG-C-DMSA, **3** and **4**). In the case of the method described by Abbott Laboratories, the hydrophilic part was maintained fixed varying the length of hydrocarbonated alkyl chains (lipid-PEG derivatives **5** and **6**). In both cases, these lipid-based particles were prepared by using preformed vesicle methods. A first screening containing PEG-C-DMSA in the formulation revealed better silencing activities than using PEG-C-DMSO in subcutaneous Hep3B-luc tumors in mice (58 versus 30%, respectively). The optimal formulations containing PEG-C-DMSA were also studied *in vitro* and *in vivo* in order to silence murine clotting factor VII mRNA, which is a prominent protein in the coagulation cascade [29]. The preparation of several SLNPs containing PEGylated lipids **5** and **6** along with other PEGylated lipids, such as PEG-Chol, was carried out to determine the transfection efficiency both *in vitro* and in several tumor models of siRNAs targeting the expression of luciferase [30].

Cationic lipids are the other major components of SLNPs. Several companies have carried out an exhaustive study to elucidate the structure-activity relationship (SAR) of these lipids. As a general rule, these cationic lipids forming SLNPs often consist of amino lipids with ionizable amine headgroups and one hydrophobic part containing generally a double-hydrocarbonated alkyl chain. Designing and synthesizing combinatorial libraries of modified cationic lipids has become the main objectives of research groups in order to improve the potency of formulations in RNA interference

and antisense technology [31]. One of the main properties of SLNPs to take into account is the dissociation constant (pK_a) of ionizable lipids since it can play an important role in both the ability to encapsulate nucleic acids and the promotion of *in vitro* and/or *in vivo* deliveries. By optimizing the design of SLNPs including the number of lipid-chain unsaturations, cationic head and linker chemistry, it could be estimated which dissociation constants would be optimal for nucleic acid delivery [32, 33].

The general structure for cationic lipids proposed by Alnylam Pharmaceuticals and Merck is shown in Figure 4B [34, 35]. These lipids are formed by a cationic head group, a linker, two hydrophobic alkyl chains and, finally, two bio-cleavable moieties containing hydrophobic chains as well. Representative cationic lipid derivatives synthesized by Alnylam are displayed in Figure 4B (compounds **7** - **10**). Test formulations containing **7** ó **10** along with a mixture of 1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC), cholesterol (Chol) and PEG-lipid at their optimal molar ratios were able to encapsulate efficiently siRNA molecules in well-established protocols. The efficacy of SLNPs to impart cellular uptake and silence FVII mRNA were determined by a simple and plate-based colorimetric assay. The use of these formulations *in vivo* containing lipids (**7** ó **10**) showed high levels of effectiveness compared to control animals with values of $ED_{50} \ll 0.1$ mg/kg.

Other cationic lipids were published [36-38]. The synthesis of cationic lipids libraries containing two hydrocarbonated alkyl chains; in which the first one contained a long unsaturated hydrophobic moiety with double bonds and the second one was formed by a short saturated alkyl chain was reported. Biodegradable groups like esters (saturated and unsaturated) and different cationic heads [36-38] were successfully introduced. A selection of cationic lipid derivatives is displayed in Figure 4B (compounds **11** ó **14**).

SiRNAs were encapsulated by impinging jet processes and the corresponding test formulations were evaluated to reduce ApoB levels *in vivo*.

The alkylation reaction with epichlorohydrin and subsequent epoxide opening either with Grignard additions or alcohol residues afforded a novel family of cationic lipids containing both ether and diether-based alkyl residues, respectively. Representative compounds are displayed in Figure 4B (compounds **15** and **16**) [39, 40]. Additionally, one of the cationic lipid alkyl chains could also be further functionalized with cholesterol. This modification allowed the preparation of amino derivatives containing different cationic heads and cholesterol residues (compounds **17** and **18**) [41]. SLNPs containing cationic lipids **17** and **18** were evaluated for *in vivo* efficacy in a luciferase mouse model in order to silence ApoB mRNA *in vivo*.

Other cationic lipids have been recently synthesized by Merck [42, 43]. The most representative ones are the cyclic amine **19** and **20**, respectively (Figure 4C). After studying luciferase activity *in vivo*, a greater efficacy was observed in both cases reducing the luciferase expression in a dose-response manner. The evaluation of the toxicity and the efficacy of these two formulations to reduce *in vivo* ApoB was also accomplished obtaining an improved tolerability in rats compared to other formulation controls.

Besides using ionizable lipids, guanidinium-based cholesterol derivatives (**21** and **22**, Figure 4C) described to deliver siRNA molecules [44]. It is well-known that having guanidinium groups (pK between 13 and 14) helps to compact zwitter ionic structures with negatively charged phosphate groups of nucleic acids. Thus, cationic lipids **21** and **22** containing cholesterol and arginine moieties were encapsulated into SLNPs and evaluated in both *in vitro* and *in vivo* targeting human ErbB3 mRNA in cancer cells and

evaluating the down-regulation in human colon cancer in xenografted mice models, respectively.

Cholesterol has also been introduced into other kinds of constructs. The synthesis and applications of a cationic carbamate series containing several cholesterol and hydrocarbonated alkyl residues covalently conjugated to N⁶-tetrakis-(3-aminopropyl)-1,3-propanediamine unit as a core structure has been published [45]. Some cationic carbamates are displayed in Figure 4C. Optimal formulations were produced by mixing cationic lipids (**23** ó **26**) with phospholipids, polyethylenglycol derivatives and a sterol, preferably cholesterol. Two optimal formulations containing the cationic carbamate **26** were used for liver siRNA delivery which reduced ApoB levels *in vivo* at a dosage of 0.5-4 mg siRNA/Kg and lung siRNA delivery with promising results as well.

Finally, Dicerna pharmaceuticals [46] developed a formulation strategy that combines polypeptide **27** containing Gly-(Arg-His)₅ residues with several palmitoyl derivatives such as 1-palmitoyl-2-azelaoyl-*sn*-glycero-3-phosphocholine (AzPC) and 1-palmitoyl-2-glutaryl-*sn*-glycero-3-phosphocholine (GIPC) cationic lipids (Figure 4C). The synthetic strategy based on the conjugation of lysophosphatidyl choline with the two selected dicarboxylic acids of different length allowed the incorporation of the cationic polypeptide sequence separated by two ethylene glycol moieties obtaining either cleavable (**28**) or stable (**29**) constructs. The efficiency of these formulations containing these novel cationic lipids was demonstrated both *in vitro* and *in vivo* by reducing the expression of a target gene in an orthotopic animal tumor model.

3.2 Lipid-oligonucleotide conjugates

As an alternative to the use of formulations obtained through electrostatic interactions, the introduction of covalent bonds between neutral or cationic lipids and nucleic acids represents an attractive approach to improve both the cellular uptake and the stability properties of nucleic acids.

The introduction of cholesterol in the 3' termini of a siRNA was the first example of this approach to silence apoB in liver and jejunum [47]. This approach has allowed the publication of patent applications and research articles covering covalent strategies to introduce lipophilic moieties at polynucleotides. In all cases, modifications containing two hydroxyl groups clearly differentiated, along with spacers of different length, are the preferred strategies to obtain nucleic acids modified with lipophilic moieties in a covalent manner.

The synthesis of several oligonucleotide cholesterol type conjugates introduced at the 5' and/or 3' end through several hydrocarbon or ether-linked moieties comprising 6 and 10 carbons of length (Table 2) has been recently described by miRagen [48]. These conjugates were designed to mimic or target miR-208, which is a family of miRNA precursors that are specifically expressed in cardiac tissues obtaining good gene knockdown activities of miR-208.

Other lipophilic moieties have been effectively introduced to modify siRNA molecules at both 3' and 5' termini [49, 50]. Sylentis SAU introduced sphingosine modifying siRNA molecules with **30** and **31**. They observed that siRNA-sphingosine conjugates (Figure 5A) were able to silence EGFP expression showing an improved stability without affecting the efficacy of naked siRNAs *in vitro* [49]. Furthermore, a series of siRNA conjugates (**33a-e**) containing neutral and cationic lipids covalently linked at their 3' and 5' termini has also been described [50]. The authors observed that lipid

modifications did not affect the RISC machinery when lipid-siRNA conjugates were transfected in the presence of lipofectamine thereby obtaining similar inhibition activities than unmodified siRNA targeting TNF- gene. Promising results were achieved when the lipid-siRNA conjugate **35**, modified with two hydrocarbonated alkyl chains, efficiently silenced TNF- expression in around 50% in the absence of commercially available cationic lipids [50].

Other strategies used for the delivery of siRNA molecules have been published [51]. These constructs are based on a cholesterol molecule covalently linked through amide bonds to alkyl or pegylated spacers and a dipeptide having phenylalanine (Phe) and lysine (Lys) residues. Additionally, the general structure can contain a cleavable *p*-aminobenzylcarbamate spacer and a siRNA binding site, which has a *p*-nitrophenyl activated carbonated moiety (**36**, Figure 5C). Therefore, modified amino siRNAs can be efficiently conjugated to the cholesterol-di-peptide structure by the nucleophilic displacement of *p*-nitrophenyl moiety thereby obtaining the corresponding carbamate molecule **37**. When these kinds of cholesterol-siRNA conjugates are taken up by cells, an expected 1,6-elimination reaction is produced, thus inducing the release of the siRNAs by lysosomal degradation inhibiting gene expression of a target mRNA. This patent application describes the ability of these siRNA conjugates containing Phe-Lys dipeptides to impart cellular uptake reducing ApoB levels in both *in vitro* and *in vivo* assays. SiRNA conjugates containing cleavable linkers showed better gene knockdown efficiencies than non-cleavable cholesterol siRNA conjugates. The authors also confirmed that the original Phe-Lys motifs present in cholesterol di-peptide siRNA conjugates were strictly necessary to decrease the production of ApoB so that the same siRNA conjugates containing other dipeptide motifs obtained less activity efficiencies in silencing ApoB. Finally, Phe-Lys dipeptide-siRNA conjugates **38** containing both

cholesterol and *N*-acetyl-*D*-galactosamine ligands were covalently linked. Carbohydrate ligands increased the efficacy of these conjugates in cellular uptake processes through receptor-mediated endocytosis due to their high binding affinities for the asialoglycoprotein receptor (ASGPR).

3.3 Peptides.

Peptides have emerged as a new class of non-viral vectors allowing the delivery of various drugs including nucleic acids through a mechanism of internalization that is still controversial and depends on the nature of the peptide. Cell penetrating peptides (CPP) also named protein transduction domains, comprise short and usually basic amino-rich peptides originating from proteins able to cross cellular membranes. Several groups have published patent applications covering delivery molecules formed by different polypeptides that are bound to nucleic acids by conjugation or by a non-covalent approach via electrostatic interactions. Polypeptide delivery systems are different peptide combinations containing one or several peptides related to extracellular receptor proteins of targeted cells, peptides that enhance the delivery or interact with nucleic acids. These systems form stable complexes with nucleic acids in the presence of serum and sometimes are able to escape from endosomal-lysosomal compartment.

3.3.1 Non covalent approach. Chimera cell delivery peptides comprising a positively charged peptide and a targeting-delivery peptide are capable of highly efficient delivery of nucleic acids into cardiac and skeletal muscle cells. Therefore the constructs may be used for treatment of a cardiac or skeletal muscle diseases or muscular dystrophy [52]. The targeting-delivery peptide is selected from MSP (muscle-specific protein) or from reported peptides to transfect antisense PNA (peptide nucleic acid) or PMO

(phosphorodiamidate morpholino oligonucleotide) to skeletal muscle with high efficiency.

In a similar system, the carrier is composed of three main peptide segments, a unit designed to bind to specific target cells, a unit designed to mediate penetration into the interior of target cells and a unit that can interact with nucleic acids designed to mediate RNAi. The complexes (peptide/ siRNA) are formed by combining the 'Her' domain for binding heregulin receptors of breast cancer cells and peptides derived from recombinant adenovirus (Ad) capsid protein. Finally, binding and transport of nucleic acids can be mediated by the polylysine, 'KIO' domain [53]. These carriers also protect the siRNA from serum nucleases.

Synthetic peptides including apolipoprotein E (ApoE) which are believed to bind with various proteins (albumin and/or immunoglobulins) that are presumably recognized by the low-density lipoprotein receptor (LDLR) pathway are able to cross the blood-brain barrier (BBB) through transcytosis [54]. Peptide constructs to deliver nucleic acids comprise a mixed sequence of hydrophilic amino acids and a blood-brain barrier agent derived from the receptor binding domain of an apolipoprotein.

Another interesting invention relates the use of combination of anti-cadherin oligonucleotides to one or more other anti-cadherin agents including peptides that bind cadherin extracellular domains useful in the treatment of acute, delayed healing and chronic wound [55]. Similarly, chimeric RNA linked to a polypeptide moiety is able to reduce DNA methylation. The RNA oligonucleotide also includes a therapeutic agent selected from a demethylating agent (e.g., 5-azacytidine (azacitidine), 5-aza-2'-deoxycytidine (decitabine)) to enhance binding to DNA methyltransferases (DNMT) [56].

Antimicrobial compositions including a CPP is combined with or conjugated to a functional nucleic acid (including morpholino oligonucleotides), such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes that impart resistance to antimicrobial drugs [57]. Likewise, different polypeptide moieties containing at least one of thymosin, any interferon or pegylated derivative, myrcludex B or any antiviral cytokine or pegylated derivative have been used to enhance the delivery of antiviral oligonucleotide chelates [58].

Another strategy for improving the delivery and stability of therapeutic oligonucleotides, named NickFect, relates to chemically modified new branched CPP with fatty acids attached to a targeting moiety that is capable of reaching specific cells or tissues of interest. The targeting moiety may be an aptamer or a targeting peptide, such as a homing peptide or a receptor ligand [59].

3.3.2 Covalent approach. The main drawbacks of using CPP not covalently linked to nucleic acids are their potential toxicity and the endosomal entrapment [60]. Linking CCP to oligonucleotides leads to well-defined, single-component systems that use only equimolar ratios of the delivery material and nucleic acid.

Several groups describe different constructs based on directed attachment to nucleic acids. One strategy is the preparation of amino functionalized oligonucleotides that are transformed to maleimido-oligonucleotides. These are able to react with modified cysteine forming a maleimido-thiol covalent bonds [61]. These therapeutic conjugates contain a peptide that specifically homes to endothelial cells in the tumour for the efficient delivery of sequence-specific antisense to cells of a selected type.

By linking a cell-penetrating peptide to a substantially uncharged antisense nucleic acid analogue via a glycine or proline amino acid, the resulting conjugates decreased the toxicity and/or enhanced cell delivery, potency, and/or tissue distribution [62].

Another approach consists of preparing peptide segments that are useful for facilitating the uptake across cell membranes, the segments are separated by aminohexanoic spacer residues and may also include non-natural amino acids [63]. Both PMO and PNA antisense are conjugated at the C-terminus of the peptide and are able to modulate dystrophin pre- mRNA splicing, thereby specifically restoring the dystrophin reading frame and generating a truncated but semi-functional dystrophin protein.

Modified and derivatised CPP with fatty acid conjugated to nucleic acids have been used to enhance transfection with less toxicity for splice correction as well as siRNA delivery [64]. Additionally, the system comprises irreversibly chloroquine-coupled compounds for endosomal escape.

Maurocalcine is the first demonstrated example of an animal toxin peptide with efficient cell penetration properties. The toxin is a 33-amino acid peptide and the invention relates to small CPPs derived from this toxin and to their use as vectors for the intracellular delivery of various drugs and agents [65]. The peptide is derivatized and coupled to oligonucleotides via a disulphide bond, thioether, thiol-maleimide or amide linkage. Other methods of linking the peptide to the oligonucleotide include the use of a C-terminal aldehyde to form an oxime, the use of a click reaction or the formation of a morpholino linkage with a basic amino acid on the peptide.

Formulations containing phase changing charge-trapped peptides and nucleic acids have been optimized to increase cellular uptake and cytoplasmatic delivery of oligonucleotides [66]. Some of these changes includes pH change induced

protonation/deprotonation, disulphide reduction, hydrolysis and proteolysis. The process involves designing candidate-phase changing, charge-trapped peptides, including designing amino acid consensus sequences with phase changing charge-trapped residues, providing a library of such peptides and screening the peptides for their efficacy in knocking down the cellular expression of a target gene.

Another invention relates to the use of a carrier peptide system that is designed to harness and/or exploit fully natural pathways for initial cell targeting and internalization, followed by retrograde transport through membranous compartments to the endoplasmic reticulum (ER) and retro-translocation from the ER to the cytosol via the ER-associated degradation pathway (ERAD) [67]. Specifically, the delivery system comprises several modules linked by cysteine side chain as branch point. One module mediates cell targeting and facilitates cellular uptake, whereas the other facilitates transport to the ER. The last one mediates translocation from the ER to the cytosol.

3.4 Small-molecule ligands

3.4.1 Small-molecule ligands for receptor mediated uptake. A number of promising small organic ligands have been developed to improve the delivery of nucleic acids by direct conjugation. These bioactive molecules have very diverse structures and are linked to nucleic acids through different bonds.

Vitamins have been conjugated to nucleic acids. In this context, α -tocopherol has been linked to nucleic acids such as siRNA providing a method for suppressing a target gene expression (apoB) *in vivo* more safely and efficiently [68]. Alternatively, α -tocopherol-

bound nucleic acids were mixed with extracted chylomicron, and then administered. Multivitamin B12 conjugates for RNAi therapeutics can assist in one or more of cell targeting, and/or the release the oligonucleotide or oligonucleotide conjugate into the cell cytoplasm [69]. The above conjugate can be formulated to provide some protection from degradation or denaturing of the oligonucleotide. The delivery systems also comprise nanoparticles which may assist cell targeting. Folic acid has been also conjugated to nucleic acids. Folate conjugates can enter cells by receptor-mediated endocytosis. Folate siRNA using different linkers targets tumors or cells of the immune system overexpressing folate receptors and causing cancer, or inflammatory diseases, respectively [70].

Other small molecules such as selected alkyl or heteroaromatic [71] or minor groove binders [72] have been attached to siRNA in order to improve cell penetration and biodistribution properties.

In addition, small organic ligands for a membrane-bound protein are covalently coupled to an oligonucleotide [73]. The ligand is coupled through a linking group that comprises a phosphate group covalently coupled to an aliphatic or an aliphatic oxide group. Ligands are designed for membrane-bound proteins, such as G-protein, or several receptors such as ion-channel receptors, tyrosine kinase-linked receptors, receptor tyrosine kinases, cytokine receptors, and receptors with intrinsic enzymatic activity.

One of the most clinically advanced conjugate is the *N*-acetylgalactosamine (GalNAc) conjugate by Alnylam Pharmaceutical. A triantennary system with optimized spacer-linked GalNAc molecules is designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor with high affinity. These constructs have effective delivery efficiency, as well as efficient cellular uptake

and/or endosomal escape properties. Improved knockdown of the target gene was obtained by subcutaneous administration. No evidence of cytokine induction, complement activation or other adverse effects was observed using a wide therapeutic window. *N*-acetylgalactosamine-conjugated melittin-like peptide platform with potent cholesterol-siRNA targeting hepatitis B virus resulted in a good in vivo therapeutic treatment without changes in cytokines [74].

A siRNA conjugate targeting the Transthyretin (TTR) gene was described for the treatment of TTR-mediated amyloidosis [75]. Similarly, a modular composition comprising the tetraGalNAc ligands attached to the passenger strand of siRNA at different 2'-positions of the ribose rings and/or at different terminal 3' and/or 5'-positions were described. These systems allow the addition of other targeting ligands such as solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents [76]. Asialoglycoprotein and folate receptors were also targeted by a galactose cluster-pharmacokinetic modulator moiety (siRNA-conjugate) with in vivo circulating and targeting properties compared to the targeting ligand alone. The pharmacokinetic modulator comprises a hydrophobic group. The delivery system also comprises a polyamine polymer not conjugated to siRNA [77].

The incorporation of a non-ionic, low-osmolar contrast agent to antisense oligonucleotides is described for treating a neurodegenerative disease [78]. These contrast agents such as iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol or ioxilan are able to cross the blood-brain-barrier and to be delivered to any tissue throughout the body, particularly the entire nervous system; this includes both the and the peripheral nervous system. Antisense oligonucleotides can bind to a survival motor neuron (SMN) gene or other related genes. In addition, morpholino antisense

oligonucleotides can bind CAG repeats, CTG repeats, CCTG repeats, or GGGCC repeats.

Targeted delivery of siRNA is accomplished by the conjugation of 5'-thio-siRNA with selective small molecule α -V- β -3 [79] or LFA-1 [80] VLA-4 [81] integrin antagonists containing appropriate linkers (e.g. ethyleneglycol) and functional groups (e.g. maleimido). Moreover, the conjugation of oligonucleotides with intracellular retrograde transport inhibitors (retro compound) such as an imine derivative or a benzodiazepine derivative increases the delivery and/or the activity of the oligonucleotide in the cell [82].

3.4.2 Multiplex structures. The delivery system called QFect for intracellular cargo delivery comprise a multicomponent system containing quinoline or naphthalene compound, an aliphatic linear or branched hydrophobic chain and an optional targeting moiety, such as homing peptide or an aptamer [83].

Another multiplexed structure invention to enhance oligonucleotide delivery comprises a modular composition. Specifically, an oligonucleotide (siRNA) with one or more linkers attached at any 3' and/or 5' end and one or more peptides attached to the linkers and optionally lipids, solubilizing groups and/or targeting ligands [84].

3.4.3 Aptamers. Targeted aptamers can be used as vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used along detection techniques to determine either the presence or the absence of specific targets in heterogeneous backgrounds.

Chimeric molecules such as aptamer-oligonucleotide conjugate have been described to improve the delivery and inhibition of the conjugated to specific cells. Specifically, a prostate-specific membrane antigen (PSMA) aptamer is conjugated to siRNA in order to inhibit nonsense-mediated mRNA decay (NMD), a surveillance mechanism which prevents the expression of mRNAs containing a premature termination codon [85].

New aptamers are developed to target tumor-associated antigen (CEA) [86]. Aptamers have been also used to release a specific drug. This is the case of an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine [87].

3.5 Polysaccharides and other natural polymers

Chitosans, glucan, dextrans and glucosamines are usually used as a delivery vehicle of therapeutic nucleic acids. These compounds may provide some advantages, including efficient transfection, bio-delivery, and availability, buffering ability or serum stability. Modified chitosan with one secondary or tertiary amine are able to introduce imidazole groups [88]. Other approaches include chitosan-arginine, chitosan-lysine and chitosan-histidine modifications [89].

Additionally, hydrophobic modified polynucleotide complexed with a glucan-containing particle have significantly reduced toxicity, are better recognized by phagocytic cells, and have a more efficient payload release and overall efficacy [90].

Several nanoparticle compositions containing chitosan have been described to improve nucleic acids delivery. A composition of a water-soluble chitosan, a thiamine pyrophosphate, a protamine, and a neutral or anionic phospholipid exhibits biostable

nanoparticle properties. This improved chitosan composition prevents aggregation of the chitosan with serum proteins [91]. Similarly, modified nanoparticle chitosan with a biocompatible layer that comprises poly(L-histidine) or a chelating agent moiety has been used for a divalent metal transporter of an olfactory nerve terminal. This method comprises nucleic acid delivery to the central nervous system [92].

Cyclodextrins are a group of cyclic polysaccharides comprising six to eight naturally occurring D(+)-glucopyranose units in alpha-(1,4) linkage. Modified forms of cyclodextrin with cationic arms covalently bound form well defined stoichiometric complexes with nucleic acids (siRNA) [93].

3.6 Synthetic polymers

A large number of polymeric systems have been developed for drug delivery [94]. Most of the polymeric systems have been developed for the delivery of small therapeutic molecules decreasing toxicity by slow degradation of polymer and / or release of the drugs in cellular conditions.

Cationic polymers such as polyethyleneimine (PEI) were one of the first polymers used for oligonucleotide delivery, since the acidic pH of the endosomes trigger the liberation of the cargo in the cytoplasm. Recently, new PEI derivatives carrying several ethylcarbamoylphenyl side chains have been proposed for siRNA delivery to decrease undesired toxicity [95]. Moreover, polypropyleneimine (PPI) has been described to deliver siRNA [96].

In a recent development a large number of polymers and conjugates have been described for delivering nucleic acids [97]. These systems include polyacrylates,

polylactides, polyesters and polyvinyl derivatives, as well as hydrophilic-hydrophobic copolymers such as polylactic-glycolic acid (PLGA), polyethyleneglycol-PLGA and others. Surprisingly, negatively charged polymers as well as amphiphilic polymers have demonstrated improved silencing efficiency and reduction of cell toxicity when used to deliver morpholino (PMO) and PNA oligomers [98]. PLGA microparticles have been described for the encapsulation of triplex-forming PNAs [99].

Specifically biodegradable polymeric made of poly(lactic) copolymerized with several hydrophilic-hydrophobic polymers such as polymetacrylic acid or poly(ethyleneglycol), or polystyrene, or poly(vinylpyridine) and more have been developed [100]. The main effect of the copolymers is the possibility of tuning up different degradabilities of the polymers depending on the amount of copolymer without compromising the low toxicity of poly(lactic) polymer [101].

Polyamides derived from diaminopropane derivatives [102], ornithine [103] or ornithine-phenylalanine [104] carrying protonable amine groups as side chains have been described as membrane lytic polymers for delivery of siRNA. Oligonucleotides as well as polyethyleneglycol and *N*-acetylgalactosamine molecules for cell targeting are conjugated to amino side chains.

Dynamic polyconjugates (DPC) made of polyvinylether copolymers with several side chains for controlling functionalization and biodegradability are probably one of the most exciting solutions for nucleic acid delivery [105]. The use of reversible linkages connecting the different components of the delivery system provides physiologically modulation of the release of the components [105]. Modified polyacetal derivatives resulting from the oxidation of polydextranes have been efficiently loaded with nucleic acids and several targeting groups with good biodegradability properties [106]

The combination of graft copolymers of polyacrylic acid with cationic lipids has been described [107]. Electrostatic interaction between polyacrylic polymers direct the binding of cationic lipids and this combination can be used for the delivery of plasmid DNA, antisense oligonucleotides and siRNA [107]. The use of ionic monomers such as dimethyloctylammonium acrylate derivatives in the polymerization of methyl methacrylate has been described for the preparation of core-shell polymers complexes with oligonucleotides designed for restoring the expression of the dystrophin protein by exon skipping mechanism [108]. Moreover, functionalization of polymers derived from dimethylacrylic acid with siRNA and ligands to facilitate endosomal escape has been developed [109].

3.7 Nanomaterials

The rapidly expanding field of nanotechnology has allowed the synthesis of well defined nanoparticles (NPs) of diverse materials. These NPs can be functionalized either with positive charges to condense DNA or RNA molecules or with therapeutic oligonucleotide sequences such as antisense, siRNA or aptamers. The functionalized biocompatible nanomaterials, such as gold, silica, iron oxide, carbon nanotubes or graphene oxide, have been used for the delivery of oligonucleotides [4].

The ability of oligonucleotide-NP conjugates, especially gold NPs, to penetrate a wide variety of cell types has been used to provide new delivery systems for therapeutic agents such as alkylating agents, DNA intercalating agents, antimetabolites or proteins of interest [110-112]. In order to avoid the large uptake of gold NPs from the reticuloendothelial system, the addition of an embolic agent such as lipid emulsions or biodegradable microspheres has been proposed [113].

Recently, gold nanoparticles have been used as a template for the preparation of hollow silica particles that can be functionalized with therapeutic oligonucleotide sequences with high load and low toxicity [114]. The coating of mesoporous silica NPs with cationic polymers has also been described as a suitable carrier for siRNA transfection [115].

Carbon nanotubes have also been developed for drug delivery. In a recent description single wall carbon nanotubes functionalized with morpholino oligonucleotides are prepared in order to form two-component self-assembling units that allow the efficient delivery of the active morpholino oligonucleotides inside of tumor cells [116]. Carbon nanotubes can be functionalized with cationic compounds such as polylysine, cationic lipids, dendrimers for targeted delivery of therapeutic oligonucleotides to specific cell types to reduce cellular toxicity [117].

4. Expert opinion

Cellular delivery of nucleic acids requires the combination of two factors: cellular penetration and escape from endosomal compartments. Much progress has been made in the last years in understanding these issues, which are crucial for the efficacy of therapeutic oligonucleotides. Cationic lipids are the most used vehicles for the preparation of novel formulations as they are the simplest and the fastest way to bind non-viral vectors with nucleic acids taking advantage of the electrostatic interactions. Solid lipid nanoparticles carrying synthetic cationic lipids, cholesterol and polyethyleneglycol have emerged as a winning alternative to liposomes. Combinatorial libraries of cationic lipids have been used for the screening and development of cationic lipids with enhanced cellular uptake and biocompatibility. Significant developments

from Alnylam Pharmaceuticals, Merck Sharp & Dohme, Dicerna pharmaceuticals and Agave Pharma in searching new cationic lipids have led to the successful delivery of oligonucleotides to liver and lung tissues.

The synthesis of an oligonucleotide covalently-linked to lipids has emerged as a promising alternative to the use of formulations. The introduction of covalent links to neutral lipids such as cholesterol (miRagen Therapeutics), sphingosine (Sylentis) or cationic lipids into nucleic acids represents an attractive approach to improve both the cellular uptake and stability properties of nucleic acids. The use of peptides as cleavable spacers between cholesterol and the oligonucleotide moieties (Hoffmann-LaRoche) adds a very interesting novelty for lysosomal degradation that generates better silencing efficiencies.

The use of peptides as non-viral vectors instead or in combination with lipids is also an expanding field for oligonucleotide delivery. This strategy is certainly advantageous for delivering non-charged nucleic acids derivatives such as PNA and PMO derivatives showing interesting results in the treatment of muscular dystrophy by exon skipping. The covalent linking of peptides to oligonucleotides seems promising given to the use of several peptides with different functions but in fact it did not provide until now interesting results until now, except in the already mentioned delivery of PNA and PMO derivatives.

The introduction of small molecule ligands into oligonucleotides in order to increase cellular uptake by receptor-mediated endocytosis has been also pursued with relatively good results in the case of the use of *N*-acetylgalactosamine conjugates that provide good uptake to hepatocytes by the asialoglycoprotein receptor. These conjugates are currently under clinical evaluation.

Synthetic and natural polymers may also play an important role in the forthcoming years. The large development in the last years directed to the delivery of small therapeutic drugs has provided good technological polymeric platforms in terms of nice cellular uptake, good biodegradability, good biocompatibility, and the possibility to incorporate several components such as ligands for receptor mediated endocytosis and molecules to facilitate endosomal escape. Low functionalization, toxicity and batch-to-batch reproducibility are still the potential negative outcomes that will be solved in the coming years with the most advanced polymers chitosans, dextrans, PLA, PLGA and PEI derivatives.

Finally, the use of nanomaterials has opened a new avenue for oligonucleotide delivery with similar advantages and disadvantages described for polymeric delivery systems. In our opinion, silica and gold nanoparticles have the best options to provide efficient functionalization and good cellular uptake properties. Recent results with graphene oxide functionalized with cationic molecules may also be an interesting alternative.

The use of nucleic acids for inhibiting the expression of target genes at the level of mRNA has obtained, in most cases, excellent results *in vitro*. However, the therapeutic applications of oligonucleotides *in vivo* have undergone multiple obstacles, such as stability and cellular internalization. Immunogenicity and cytotoxicity are other issues to take into account. These hurdles clearly reduce the possibilities of success for these therapies although some proof-of-principle studies have demonstrated promising silencing activities without secondary effects. The development of safe and efficient delivery systems continues to be challenging, but the last developments showed improved *in vivo* efficacy, thus gaining a foothold in therapeutics.

Acknowledgements

This work is supported by the European Commission (Grant NMP4-LA-2011-262943, MULTIFUN), by the Spanish Ministry of Education (Grant CTQ2010-20541), the Generalitat de Catalunya (2009/SGR/208) and the Instituto de Salud Carlos III (CB06_01_0019).

References

1. **Kole R, Krainer AR, Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. *Nature Rev. Drug Discov.* 2012; 11; 125-40. [PubMed: 22262036]

**Excellent review on the therapeutic potential of nucleic acids with special mention to steric-blocking oligonucleotides

2. Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. *Curr. Opin. Chem. Bio.* 2006; 10: 607-614. [PubMed: 17049298]

3. Joergensen M, Agerholm-Larsen B, Nielsen PE, et al. Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry. *Oligonucleotides* 2011, 21; 29-37. [PubMed: 21235293]

4. *Zhou J, Shum K-T, Burnett JC, et al. Nanoparticle-based delivery of RNAi therapeutics: Progress and challenges. *Pharmaceuticals* 2013, 6; 85-107. [PubMed: 23667320]

*Excellent review dedicated to analyze the strategies for an efficient nucleic acid delivery using nanoobjects.

5. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. *Expert Opin. Investig. Drugs* 2005, 14; 671-682. [PubMed: 15926872]

6. Dixon DL, Sisson EM, Butler M, et al. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. *J. Cardiovasc. Nurs.* 2013, in press [PubMed: 24231894]

7. de Smet MD, Meenken CJ, van den Horn GJ, et al. Formivirsen ó a phosphorothioate oligonucleotide for the treatment of CMV retinitis. *Ocul. Immunol. Inflamm.* 1999, 7, 189-198. [PubMed: 10611727]
8. Couto LB, High KA. Viral vector-mediated RNA interference. *Curr. Opin. Pharmacol.* 2010, 5; 534-542. [PubMed: 20620113]
9. Jafari M, Soltani M, Naahidi S, et al. Nonviral approach for targeted nucleic acid delivery. *Curr. Med. Chem.* 2012, 19; 197-208. [PubMed: 21337501]
10. Zhi D, Zhang S, Cui S, et al. The headgroup evolution of cationic lipids for gene delivery. *Bioconjug. Chem.* 2013, 24; 487-519. [PubMed: 23461774]
11. Buyens K, De Smedt SC, Braeckmans K et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. *J. Control Release* 2012, 158; 362-70. [PubMed: 22023849]
12. Montana G, Bondi ML, Carrotta R. et al. Employment of cationic solid-lipid nanoparticles as RNA carriers. *Bioconjug. Chem.* 2007, 18; 302-8. [PubMed: 17253655]
13. Yousefi A, Storm G, Schiffelers R et al. Trends in polymeric delivery of nucleic acids to tumors. *J. Control Release* 2013, 170; 209-18. [PubMed: 23770011]
14. Trabulo S, Cardoso AL, Cardoso AM, et al. Cell-penetrating peptides as nucleic acid delivery systems: from biophysics to biological applications. *Curr. Pharm. Des.* 2013, 19; 2895-923. [PubMed: 23140453]

15. Grijalvo S, Ocampo SM, Perales JC, et al. Synthesis of oligonucleotides carrying aminolipid groups at the 3' end for RNA interference studies. *J.Org.Chem.* 2010, 75; 6806-13. [PubMed: 20863084]

16. Troiber C, Wagner E. Nucleic acid carriers based on precise polymer conjugates. *Bioconjug. Chem.* 2011, 22; 1737-52. [PubMed: 21749135]

17. Liu H, Topping T, Dong M, et al. DNA-templated covalent coupling of G4 PAMAM dendrimers. *J. Am. Chem. Soc.* 2010, 132; 18054-56. [PubMed: 21133363]

18. **Soutschek J, Akinc A, Bramlage B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* 2004, 432; 173-8. [PubMed: 15538359]

- **First paper demonstrating the in vivo efficacy of siRNAs modified with cholesterol

19. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. *Nature Rev. Drug Discov.* 2010, 9; 57-67. [PubMed: 20043028]

20. Famulok M. Exploring chemical space with aptamers. *J. Med. Chem.*, 2009, 52: 6951-7. [PubMed: 19877651]

21. Ruckman JM, Green LS, Beeson J. et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). *J. Biol. Chem.* 1998, 273: 20556-67. [PubMed: 9685413]

22. *Semple SC, Akinc A, Chen J. et al. Rational design of cationic lipids for siRNA delivery. *Nat. Biotechnol.* 2010, 28; 172-6. [PubMed: 20081866]

- *A rational method for designing cationic lipids with enhanced delivery of nucleic acids

23. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. *Curr. Drug Discov. Technol.* 2011, 8; 207-27. [PubMed: 21291409]
24. Templeton N. Cationic liposomes as in vivo delivery vehicles. *Biosci. Rep.* 2002, 22; 283-95. [PubMed: 12428905]
25. *Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. *Nature* 2006. 441; 111-4. [PubMed: 16565705]
- *First paper showing silencing of ApoB gene in monkeys using cholesterol-siRNAs
26. Gomes da Silva L, Fonseca NA, Moura V, et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. *Acc. Chem. Res.* 2012, 45; 1163-71.
27. de Fougerolles A, Vornlocher H-P, Maraganore J, et al. Interference with disease: a progress report on siRNA-based therapeutics. *Nature Rev. Drug Discov.* 2007, 6; 443-53.
28. Alnylam Pharmaceuticals. Di-aliphatic substituted pegylated lipids. 2013. WO2013049328 A1
29. Alnylam Pharmaceuticals. Pegylated lipids and their use for drug delivery. 2012. WO2012099755 A1
30. Abbott Laboratories. Cationic lipids and uses thereof. 2010. US20100055168 A1; US20100055169 A1

31. **Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat. Biotechnol.* 2008, 26; 561-9. [PubMed: 3014185]

**Development of novel lipidoids for oligonucleotide administration. The more promising candidates are evaluated in three different animal models.

32. Zhang J, Fan H, Levorse DA, et al. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR and the impact of lipid pK_a on cationic lipid-biomembrane interactions. *Langmuir* 2011, 27; 1907-14.

33. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. *Angew. Chem. Int. Ed.* 2012, 51; 8529-33. [PubMed: 3470698]

34. Alnylam Pharmaceuticals. Biodegradable lipids for the delivery of active agents. 2011. WO2013086354 A1; WO201153493 A1

35. Alnylam Pharmaceuticals. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of nucleic acids. WO2013086322 A1

36. Merck Sharp & Dohme Corporation. Novel low molecular weight cationic lipids for oligonucleotide delivery. WO2012054365 A2; WO2011153120 A1

37. Merck Sharp & Dohme Corporation. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery. WO2013116126 A1

38. Merck Sharp & Dohme Corporation. Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery. WO2013158579 A1

39. Merck Sharp & Dohme Corporation. Low molecular weight cationic lipids for oligonucleotide delivery. 2012. WO2012044638 A1
40. Merck Sharp & Dohme Corporation. Diether based biodegradable cationic lipids for siRNA delivery. 2013. WO2013148541 A1
41. Merck Sharp & Dohme Corporation. Novel cationic lipids with various head groups for oligonucleotide delivery. 2011. WO2011022460 A1
42. Merck Sharp & Dohme Corporation. Ring constrained cationic lipids for oligonucleotide delivery. WO2012162210 A1
43. Merck Sharp & Dohme Corporation. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery. WO2012061259 A1
44. Alnylam Pharmaceuticals. Branched cationic lipids for nucleic acids delivery system. 2010. WO2010056403 A1
45. Agave Pharma Inc. Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules. 2010. WO2010135207 A1
46. Dicerna Pharmaceuticals. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells. 2013. WO2013032643 A2
47. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25; 11149-57. [PubMed: 17873866]
48. Miragen Therapeutics. Lipophilic polynucleotide conjugates. 2010. WO2010129672 A1

49. Sylentis SAU. Sphingosine-bound siRNA. 2012. US2012142765 A1
50. Consejo Superior de Investigaciones Científicas. Lipophilic derivatives of nucleic acids. 2011. WO2011135138 A1
51. F. Hoffmann-LaRoche AG. Small molecule conjugates for intracellular delivery of nucleic acids. 2012. WO2012089352 A1
52. Isis Innovation. Conjugates for delivery of biologically active compounds. 2011. WO2011064552 A1
53. Cedars Sinai Medical Center. Targeted delivery system. 2010. WO2010085665 A2
54. Mayo Foundation for medical education and research. Peptide-mediated delivery of active agents across the blood-brain barrier. 2013. WO2013082286 A1
55. Coda therapeutics Inc. Compositions and treatments based on cadherin modulation. 2013. WO2013148736 A1
56. Beth Israel Deaconess Medical Center Inc. Chimeric RNA oligonucleotides and uses thereof. 2012. WO2012142480 A1
57. Yale university. Antimicrobial compositions and methods of use thereof. 2013. WO2013044116 A1
58. Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods. 2013. WO2013170386 A1
59. Cepep III AB et al. A system for cargo delivery into the cells. 2012. WO2012113846 A1

60. Lundberg, P., El-Andaloussi, S., Sutlu, T. et al. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 2007, 21: 2664-71. [PubMed: 17463227]
 61. Sloan-Kettering institute for cancer research. Peptide-conjugated oligonucleotide therapeutic and method of making and using same. 2011. US2011003754 A1
 62. AVI Biopharma Inc., Peptide-oligonucleotide conjugate. 2012. WO2012150960 A1
 63. *Gait MJ, Arzumanov AA, Saleh AF, et al. Peptides. 2013. WO2013030569 A2
- *Patent describing the preparation of oligonucleotide-peptide conjugates.
64. Ahmed K, El Andaloussi S, Guterstam P, et al. Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds. 2010. WO2010039088 A1
 65. Commissariat à l'énergie atomique et aux énergies alternatives, INSERM, Université Joseph Fourier. Small efficient cell-penetrating peptides derived from the scorpion toxin Maurocalcine. 2012. WO2012176138 A2
 66. Dicerna Pharmaceuticals Inc. Phase changing formulations of nucleic acids payloads. 2012. WO2012173994 A2
 67. Cenix Bioscience GmbH. Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes. 2012. WO2012101235 A1
 68. National University Corp. Tokyo Medical and Dental University. System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron. 2010. US2010234282 A1

69. Access Pharmaceuticals Inc. Multivitamin targeting of RNAi therapeutics. 2012. WO2012030745 A1

70. Endocyte Inc. and Perdue Research Foundation. Folate targeting of nucleotides. 2010. WO2010045584 A1

71. Consejo Superior de Investigaciones Cientificas. Modified oligonucleotides as regulators of gene expression. 2011. WO2011135141 A1

72. Goorve Biopharma Corp. Enhanced biodistribution of oligomers. 2012. WO2012119051 A2

73. The University of North Caroline at Chapell Hill, Targeted intracellular delivery of oligonucleotides via conjugation with small molecule ligands. 2011. WO2011126937 A1

74. Arrowhead Madison Inc. - Peptide-Based In Vivo siRNA Delivery System. US2013281658 A1

75. **Alynham Pharmaceuticals. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases. 2013. WO2013075035 A1

**Patent describing the efficacy of the GalNAc conjugation to siRNA molecules with special emphasis to the treatment of transthyretin amyloidosis. The conjugates have shown positive results in recent clinical trials.

76. Merck, Sharp & Dohme Corp. Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides. 2013. WO2013166121 A1

77. Arrowhead Res Corp. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA. 2013. KR20137015388 20111215

78. Burghes A. Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease. 2013. WO2013086207 A1
79. Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3. 2013. WO2013110679 A1
80. Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1. 2013. WO2013110679 A1
81. Hoffmann La Roche AG. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4. 2013. WO2013110680 A1
82. The University of North Caroline at Chapell Hill and Commissariat a l'energie atomique et aux energies alternatives. Small molecules that enhance the activity of oligonucleotides. 2013. WO2013123217 A1
83. GE Healthcare Biosciences AB. System for improved delivery of gene modulating compounds. 2011. WO2011115555 A1
84. Merck, Sharp & Dohme Corp. Novel single chemical entities and methods for delivery of oligonucleotides. 2011. WO2011126974 A1
85. University of Miami. Aptamer-targeted siRNA to inhibit non sense mediated decay. WO2011005566 A2
86. Smith C. Compositions comprising nucleic acid aptamers. 2010. US20100254901 A1
87. University of Columbia. Aptamer mediated drug release. 2010. WO2010111466 A1
88. Krishnendu R, Bilal G, Sudhir K. Modified polysaccharide-based delivery of nucleic acids. 2010. US2010311654 A1

89. Synedgen Inc. Nucleic acid delivery using modified chitosans. 2010. WO2010088565 A1
90. RXI pharmaceuticals Corp. Formulations and methods for targeted delivery to phagocyte cells. 2011. WO2011109698 A1
91. Chong Kun Dang Pharmaceuticals Inc. Novel composition for gene delivery. 2013. WO2013070010 A1
92. University of South Florida. Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation. 2013. WO2013040295 A2
93. RGO Biosciences LLC, Cyclodextrin conjugates. 2010. WO2010017328 A2
94. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug. Deliv. Rev. 2013, 65: 60-70. [PubMed: 22981753]
95. University of Strasbourg & CNRS. Polymers for delivering molecules of interest. 2011. WO2011120953 A1
96. University of Rutgers. Compositions and methods for delivering nucleic acids molecules and treating cancer. 2012. 2011. WO2012024396 A2, US20110281787 A1
97. Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods. 2013. WO2013126564 A1.
98. Charlotte Mecklenburg Hospital. Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same. 2011. WO2011143008 A1
99. University of Yale. Polymeric materials loaded with mutagenic and recombinagenic nucleic acids. 2011. WO2011053989 A2

100. Nanogen Pharmaceuticals. Polymeric nanoparticles and a process of preparation thereof. 2013. WO2013160773 A2
101. Merck, Sharp & Dohme, Membrane lytic poly(amido-amine) polymers for the delivery of oligonucleotides. 2012. WO2012082574 A1
102. Merck, Sharp & Dohme, Polyamide polymers for the delivery of oligonucleotides. 2012. 2011. WO2012068187 A1, WO2011115862 A1
103. Merck, Sharp & Dohme, Poly(ornithine) homopolymers for the delivery of oligonucleotides. 2013. WO2013016157 A1
104. Rozema D.B. & Wakefield D.H. Polyconjugates for in vivo delivery of polynucleotides. 2012. US2012230938 A1
105. *Mersana therapeutics Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof. 2011. WO2011120053 A1
- *Description of clever reversible linkages that provide modulation on the release of therapeutic oligonucleotides.
106. University of Ferrara. Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating Duchenne muscular dystrophy. 2011. WO2011045747 A1
107. Rutgers, The State University of New Jersey. Graft copolymer polyelectrolyte complexes for drug delivery. 2013. US20130183379 A1
108. Alnylam Pharmaceuticals Inc. Multifunctional copolymers for nucleic acid delivery. 2011. WO2011163121 A1

109. Yale University. Methods of treating inflammatory and autoimmune diseases and disorders. 2013. WO2013155493 A1
110. Northwestern University. Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers. 2011. WO2011028850 A1
111. University of Siracuse. Synthesis and method for delivery of DNA-binding chemotherapy drugs using nanoparticles. 2012. WO2012061402 A2
112. Dar-Bin S, Chen-Sheng Y, Dong-Huang C. et al. Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition. 2012. US2012027861 A1
113. Northwestern University. Localized delivery of nanoparticles for therapeutic and diagnostic applications. 2011. WO2011017456 A2
114. University of Chung. Nanoparticle-based gene delivery systems. 2011. WO2011055888 A1
115. University of California. Cationic polymer coated mesoporous silica nanoparticles and uses thereof. 2012. US20122007795 A1, WO2012009448 A2
116. Sloan-Kettering Institute for Cancer Research. Targeted self-assembly of functionalized carbon nanotubes on tumors. 2013. WO2013101983 A2
117. Sanford Burnham Medical Research institute. 2011. Delivery of agents using interfering nanoparticles. WO2011116152 A2

Figure 1. Chemical modifications carried out to improve the stability of oligonucleotides

Table 1. Antisense and siRNA oligonucleotides in the clinical pipeline

Drug	Carrier	Target	Disease	Phase	Company	Status*
Macugen	RNA aptamer	VEGF	Age-related macular degeneration	III	Pfizer	approved
Mipomersen	ASO	ApoB	Hypercholesterolaemia	III	ISIS	approved
Oblimersen	ASO	Bcl2	cancer	II	Genta	completed (NCT00064259)
Custirsen	ASO	Clusterin	Prostate cancer	III	OncoGenex	ongoing (NCT01578655)
IMO-2055	ASO	TLR9	Renal cell carcinoma	II	Idera Pharmaceuticals	completed (NCT00729053)
PF04523655	siRNA	RTP801/REDD1	Wet AMD and DME	II	Quark Pharmaceuticals	completed (NCT01445899)
Excellair	siRNA	SYK kinase	Asthma	II	ZaBeCor	ongoing
TD101	siRNA	Keratin 6a (N171 mutation)	Pachyonychia Congenita	Ib	TransDerm	completed (NCT00716014)
AGN211745	siRNA	VEGFRI	Age-related macular degeneration	II	Allergan	completed (NCT00395057)
ISIS-STAT3Rx	ASO	STAT3	DLBCL lymphoma	I/II	Isis Pharmaceuticals	ongoing (NCT01563302)
ISIS-PTP1BRx	ASO	PTP-1B	Type 2 Diabetes	II		ongoing (NCT01918865)
Eteplirsen (AVI-4658)	PMO	Exon 5	Duchenne muscular dystrophy	II	Sarepta Therapeutics	completed (NCT01396239)
Bevasiranib	siRNA	VEGF	AMD	III	Opko Health, Inc	completed (NCT00499590)
ALN-VSP02	siRNA		Solid tumors	I	Alnylam Pharmaceuticals	completed (NCT01158079)
Sirna-027	siRNA	AMD	Age-related macular degeneration	I/II	Allergan/Sirna Therapeutics	completed (NCT00363714)
SYL040012	siRNA	ADRB2	Ocular hypertension	I/II	Sylentis	completed (NCT01227291)
SYL1001	siRNA	TRPV1	Dry eye	I/II		ongoing (NCT01776658)
CALAA-01	siRNA	RRM2	Solid tumor cancers	I	Calando Pharmaceuticals	completed (NCT00689065)
ALN-TTRSC	siRNA	TTR	TTR cardiac amyloidosis	II	Alnylam Pharmaceuticals	ongoing (NCT01981837)
ALN-TTR02	siRNA			II		ongoing (NCT01617967)
ALN-RSV01	siRNA	RSV	RSV infection	IIb		completed (NCT01065935)
ALN-PCS02	siRNA	PCSK9	Hypercholesterolemia	I		completed (NCT01437059)
TKM-080301	siRNA	PLK1	Advanced solid tumors	II	Tekmira Pharmaceuticals	ongoing (NCT01262235)
SPC2996	LNA PS	Bcl2	Chronic lymphocytic leukemia	I/II	Santaris Pharma	completed (NCT00285103)
Atu027-I-02	siRNA	PKN3	Metastatic pancreatic cancer	I/II	Silence Therapeutics	ongoing (NCT01808638)
RXI-109	siRNA	CTGF	Hypertrophic scar	II	RXi Pharmaceuticals	ongoing (NCT02030275)
CRLX-101	siRNA	Topoisomerase I	Rectal cancer	II	Cerulean Pharma	ongoing (NCT02010567)
QPI-1002	siRNA	P53	ischemia-reperfusion-related injuries	I/II	Quark Pharmaceuticals	ongoing (NCT00802347)

*<http://www.clinicaltrials.gov>

Figure 2. Strategies to deliver nucleic acids (cargo) by using non-viral carriers: A. Formulation and B. Covalent approaches.

Figure 3. Some of mechanisms used for the inhibition of gene expression implies antisense inhibition with the intervention of RNase H (A), RNA interference mechanism (B) or steric-blocking of mRNA (C).

Figure 4. General structures of modified PEGylated lipids (A), representative ionizable cationic lipids containing biodegradable moieties (B) and other constructs (C) used in formulations.

C. Other constructs

Table 2. Potential sites of conjugation with cholesterol modifying mir-208 molecules at both 3' and 5' termini

Entry	Spacer	R	Site of conjugation
1			3'
2			5'
3			3'

= Solid support

Figure 5. Synthetic strategy to introduce sphingosine (A), neutral and cationic lipids (B) at both 3' and 5' termini and other constructs (C)

A. Sphingosine

Modification

3'-termini

5'-termini (post-synthetic approach)

B. Neutral and cationic lipids

Modification

3'-termini

5'-termini (phosphoramidite chemistry)

C. Other constructs

where Y = $-(CH_2)_3-$ or $C(O)N-(CH_2-CH_2-O)_n-CH_2-CH_2-$

siRNA conjugate